Effective drug combinations in breast, colon and pancreatic cancer cells
Open accessThe DOI matches its Crossref record; 40 of the 43 references it cites were found in a registry or an index.
Abstract
Combinations of anti-cancer drugs can overcome resistance and provide new treatments 1,2 . The number of possible drug combinations vastly exceeds what could be tested clinically. Efforts to systematically identify active combinations and the tissues and molecular contexts in which they are most effective could accelerate the development of combination treatments. Here we evaluate the potency and efficacy of 2,025 clinically relevant two-drug combinations, generating a dataset encompassing 125 molecularly characterized breast, colorectal and pancreatic cancer cell lines. We show that synergy between drugs is rare and highly context-dependent, and that combinations of targeted agents are most likely to be synergistic. We incorporate multi-omic molecular features to identify combination biomarkers and specify synergistic drug combinations and their active contexts, including in basal-like breast cancer, and microsatellite-stable or KRAS -mutant colon cancer. Our results show that irinotecan and CHEK1 inhibition have synergistic effects in microsatellite-stable or KRAS – TP53 double-mutant colon cancer cells, leading to apoptosis and suppression of tumour xenograft growth. This study identifies clinically relevant effective drug combinations in distinct molecular subpopulations and is a resource to guide rational efforts to develop combinatorial drug treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures












Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies simply compare TV at a single day using t test, or use survival analysis to compare the time-to-event (i.e., time for TV to reach a threshold) between groups (4–6, 23).”
From Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SN-38, the in vivo active metabolite of TOP1 inhibitor Irinotecan, showed strong synergy with the CHEK1 inhibitor rabusertib under the Bliss model in multiple colon cell lines.”
From Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, such in vivo validation studies only showed that synergy exists under the HSA model but not the more stringent Bliss model.”
From Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A recent study systematically evaluated clinically relevant two-drug combinations in cancer cell lines and identified synergistic effects between chemotherapy agents and drugs targeting apoptotic signaling or cell cycle inhibitors in distinct molecular subpopulations [236].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [236]
The cited source says what the claim attributes to it.
In the citing paper
“In the context of CRC, the study found that irinotecan and CHK1 inhibition had a synergistic anticancer effect in microsatellite stable (MSS) or KRAS-TP53 double-mutant colon cancer cells.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [236]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Y., Yan, H., Frost, P., Gera, J., & Lichtenstein, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0068 · Cited by 368 · cited 1×
“This combination may work by inhibiting feedback activation of AKT in HER2 breast cancer due to mTOR inhibitor-induced activation of PI3K signalling 13 .”
RetractedUniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721 · cited 6×
“…known to be mutated, amplified or homozygously deleted in human cancers 5 (number of features = 1,073), CELLector signatures 34 ( n = 227 for breast, n = 261 for colon), RNA-seq gene expression 35 ( n = 1,184; original dataset accession number E-MTAB-3983), CRIS 36 and PAM50 37,38 classifications.”
InfluentialYang, W., Soares, J., Greninger, P., Edelman, E. J., Lightfoot, H., Forbes, S., Bindal, N., Beare, D., Smith, J. A., Thompson, I. R., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1111 · Cited by 4,051 · cited 1×
“…concentrations were selected based on primary literature, in vitro data of minimum concentrations inhibiting relevant target activity and viability 31 , clinical data indicating achievable human plasma concentrations, or where known concentrations that induce sensitivity in a biomarker positive…”
Self-citationTHE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · cited 3×
“…a curated panel of genes composed of targets of the drugs used, additional members of the BCL2 family and apoptosis-associated genes 39 , genes annotated as clinically relevant for cancer 40 , and genes whose mutations were listed as features in the MOBEMs 5,40 and CELLector 5,34,40 feature files.”
Self-citationUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051 · cited 1×
“4f), with synergy occurring exclusively in BRAF -mutant cell lines 16 (4 or 6 synergistic cell lines, respectively).”
The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases
Orchard, S., Ammari, M., Aranda, B., Breuza, L., Briganti, L., Broackes-Carter, F., Campbell, N. H., Chavali, G., Chen, C., del-Toro, N., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1115 · Cited by 1,831
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · cited 1×
“…using targeted anti-cancer agents have the potential to overcome resistance, enhance the response to existing drugs, reduce dose-limiting single agent toxicity and expand the range of treatments 2 , as exemplified by triple combination therapy for patients with BRAF-mutant colorectal cancer 3 .”
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653 · cited 1×
“Similarly, our data could improve computational approaches, which currently lack training datasets, for predicting effective drug combinations in different contexts 4,28,29 .”
Griffith, M., Spies, N. C., Krysiak, K., McMichael, J. F., Coffman, A. C., Danos, A. M., Ainscough, B. J., Ramirez, C. A., Rieke, D. T., Kujan, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3774 · Cited by 628
Tabernero, J., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02088 · Cited by 569 · cited 1×
“Combinations of EGFR antibodies and BRAF inhibitors are a clinically approved regimen in BRAF -mutant metastatic colorectal cancer 17 .”
Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0492 · Cited by 413
An unbiased oncology compound screen to identify novel combination strategies
O'Neil, J., Benita, Y., Feldman, I., Chenard, M., Roberts, B., Liu, Y., Li, J., Kral, A., Lejnine, S., Loboda, A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0843 · Cited by 407 · cited 3×
“We demonstrate that synergy is rare, as has been described 6,7 , that it varies within tissues and between molecular backgrounds, and that combinations of targeted drugs are more likely to synergise than combinations involving chemotherapy.”
Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies
Liston, D. R., & Davis, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3083 · Cited by 395 · cited 1×
“Screening concentrations (Supplementary Table 1) typically did not exceed 10 μM and were in the range of human plasma exposures achievable in patients 32 .”
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Lopez, J. S., & Banerji, U. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.96 · Cited by 394
Menden, M. P., Wang, D., Mason, M. J., Szalai, B., Bulusu, K. C., Guan, Y., Yu, T., Kang, J., Jeon, M., Wolfinger, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09799-2 · Cited by 363 · cited 4×
“However, our ability to predict effective combinations is limited 4 .”
InfluentialSelf-citationHolbeck, S. L., Camalier, R., Crowell, J. A., Govindharajulu, J. P., Hollingshead, M., Anderson, L. W., Polley, E., Rubinstein, L., Srivastava, A., Wilsker, D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0489 · Cited by 359 · cited 3×
“We produced 296,707 drug combination viability measurements for 108,259 combination–cell line pairs, making it the second largest drug combination dataset by number of combinations and experiments, with the largest number of cell lines tested 4,6–8 .”
Why do BCL-2 inhibitors work and where should we use them in the clinic?
Montero, J., & Letai, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.183 · Cited by 327
Isella, C., Brundu, F., Bellomo, S. E., Galimi, F., Zanella, E., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 302 · cited 4×
“UPID mapping was not possible for chemotherapeutics, PAM50, CRIS, and not done for methylation sites not associated with a cancer driver gene.”
InfluentialSelf-citation(1997) · PubMed · Cited by 238
Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer
Garcia-Alonso, L., Iorio, F., Matchan, A., Fonseca, N., Jaaks, P., Peat, G., Pignatelli, M., Falcone, F., Benes, C. H., Dunham, I., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1679 · Cited by 202 · cited 1×
“…known to be mutated, amplified or homozygously deleted in human cancers 5 (number of features = 1,073), CELLector signatures 34 ( n = 227 for breast, n = 261 for colon), RNA-seq gene expression 35 ( n = 1,184; original dataset accession number E-MTAB-3983), CRIS 36 and PAM50 37,38 classifications.”
Self-citationAnticancer therapy with checkpoint inhibitors: what, where and when?
Garrett, M. D., & Collins, I. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.014 · Cited by 202 · cited 1×
“of CHEK1 inhibition, but not CHEK2 inhibition, with DNA-damaging agents such as topoisomerase 1 inhibitors 23 .”
Quantifying drug combination synergy along potency and efficacy axes
Meyer, C. T., Wooten, D. J., Paudel, B. B., Bauer, J., Hardeman, K. N., Westover, D., Lovly, C. M., Harris, L. A., Tyson, D. R., & Quaranta, V. (2019) · Cell Systems · doi:10.1016/j.cels.2019.01.003 · Cited by 202 · cited 1×
“We establish that evaluating combination potency and efficacy are complementary, a recently introduced concept 10 , and could identify combinations leading to dose reduction, improved efficacy or both, relative to single agents.”
van der Meer, D., Barthorpe, S., Yang, W., Lightfoot, H., Hall, C., Gilbert, J., Francies, H. E., & Garnett, M. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky872 · Cited by 195
Self-citationPredicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data
Sidorov, P., Naulaerts, S., Ariey-Bonnet, J., Pasquier, E., & Ballester, P. J. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00509 · Cited by 152
Tse, A. N., Rendahl, K. G., Sheikh, T., Cheema, H., Aardalen, K., Embry, M., Ma, S., Moler, E. J., Ni, Z. J., Lopes de Menezes, D. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1424 · Cited by 147
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
Walton, M. I., Eve, P. D., Hayes, A., Valenti, M. R., Brandon, A. D. H., Box, G., Boxall, K. J., Aherne, G. W., Eccles, S. A., Raynaud, F. I., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0938 · Cited by 110
Cancer research needs a better map
Boehm, J. S., Garnett, M. J., Adams, D. J., Francies, H. E., Golub, T. R., Hahn, W. C., Iorio, F., McFarland, J. M., Parts, L., & Vázquez, F. (2021) · Nature · doi:10.1038/d41586-021-00182-0 · Cited by 101 · cited 1×
“The data presented here are a rich resource and augment existing genomic, transcriptomic and functional datasets for cell lines available as part of the Cancer Dependency Map 27 .”
Self-citationTolcher, A. W., Peng, W., & Calvo, E. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0349 · Cited by 99
GDSCTools for mining pharmacogenomic interactions in cancer
Cokelaer, T., Chen, E. D., Iorio, F., Menden, M. P., Lightfoot, H. W., Sáez-Rodríguez, J., & Garnett, M. J. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx744 · Cited by 79
Self-citationMultilevel models Improve precision and Speed of IC 50 Estimates
Vis, D. J., Bombardelli, L., Lightfoot, H., Iorio, F., Garnett, M. J., & Wessels, L. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.15 · Cited by 71 · cited 1×
“All library drug dose responses were fitted as a two-parameter sigmoid function 33 .”
Self-citationLidsky, M., Antoun, G., Speicher, P., Adams, B., Turley, R., Augustine, C., Tyler, D., & Ali-Osman, F. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.532432 · Cited by 62 · cited 1×
“Low expression of NRAS predicted response to dabrafenib (BRAF inhibitor) plus trametinib (MEK1/2 inhibitor) in breast, consistent with NRAS expression modulating BRAF inhibitor sensitivity 19 .”
A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines
Flobak, Å., Niederdorfer, B., Nakstad, V. T., Thommesen, L., Klinkenberg, G., & Lægreid, A. (2019) · Scientific Data · doi:10.1038/s41597-019-0255-7 · Cited by 60 · cited 1×
“We demonstrate that synergy is rare, as has been described 6,7 , that it varies within tissues and between molecular backgrounds, and that combinations of targeted drugs are more likely to synergise than combinations involving chemotherapy.”
Weiss, G. J., Donehower, R. C., Iyengar, T., Ramanathan, R. K., Lewandowski, K., Westin, E. H., Hurt, K. C., Hynes, S. M., Anthony, S. P., & McKane, S. W. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9815-9 · Cited by 59
CELLector: Genomics-Guided Selection of Cancer In Vitro Models
Najgebauer, H., Yang, M., Francies, H. E., Pacini, C., Stronach, E. A., Garnett, M. J., Saez-Rodriguez, J., & Iorio, F. (2020) · Cell Systems · doi:10.1016/j.cels.2020.04.007 · Cited by 43
Self-citationLAS: A Software Platform to Support Oncological Data Management
Baralis, E., Bertotti, A., Fiori, A., & Grand, A. (2012) · Journal of Medical Systems · doi:10.1007/s10916-012-9891-6 · Cited by 35
Self-citationRas–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
Lee, H.-J., Cao, Y., Pham, V. C., Blackwood, E. R., WILSON, C. A., Evangelista, M., Klijn, C. N., Stokoe, D., & Settleman, J. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0504 · Cited by 22
Ebbert, M., Bastien, R. R. L., Rowe, L. R., Miller, P. A., Anderson, D., Boucher, K. M., Pappas, L. M., Fauron, C. M. ‐., Lyons, B. W., Dowell, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10597 · Cited by 7 · cited 1×
“…known to be mutated, amplified or homozygously deleted in human cancers 5 (number of features = 1,073), CELLector signatures 34 ( n = 227 for breast, n = 261 for colon), RNA-seq gene expression 35 ( n = 1,184; original dataset accession number E-MTAB-3983), CRIS 36 and PAM50 37,38 classifications.”
Research works printed but not linked: 1
- Jassal B The reactome pathway knowledgebase Nucleic Acids Res. 2020 48 D498 D503 31691815 PMC7145712
Cited by
Smart nanoparticles for cancer therapy
Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Organometallic anti-tumor agents: targeting from biomolecules to dynamic bioprocesses
Peng, K., Zheng, Y., Xia, W., & Mao, Z.-W. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00757f · Cited by 188
Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology
Ji, S., Li, F., Fu, Z., Wu, G., Wu, Y. C., Lin, Y., Lu, D., Song, Y., Cui, P., Yang, Z., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg3358 · Cited by 158
“Consistently, a recent high-throughput drug combination test also showed the high synergy in targeting receptor tyrosine kinase and PI3K-mTOR pathway across breast, colon, and pancreatic cancer cell lines (46).”
BackgroundLiu, X., Song, C., Liu, S., Li, M., Zhou, X., & Zhang, W. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac579 · Cited by 116
Metadata
- Authors
- Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., van der Meer, D., Yang, W., Beck, A., Mironenko, T., Hall, C., Hall, J., Mali, I., Richardson, L., Tolley, C., Morris, J., Thomas, F., Lleshi, E., Aben, N., Benes, C. H., Bertotti, A., Trusolino, L., Wessels, L., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute (GB)
- Candiolo Cancer Institute (IT)
- The Netherlands Cancer Institute (NL)
- Harvard University (US)
- Corresponding author
- Garnett, Mathew J.
- ORCID
- Jaaks, Patricia
- Coker, Elizabeth A.
- Edwards, Olivia
- Carpenter, Emma F.
- Leto, Simonetta M.
- Sassi, Francesco
- Lightfoot, Howard
- Barthorpe, Syd
- van der Meer, Dieudonne
- Yang, Wanjuan
- Beck, Alexandra
- Mironenko, Tatiana
- Hall, Caitlin
- Hall, James
- Mali, Iman
- Richardson, Laura
- Tolley, Charlotte
- Thomas, Frances
- Benes, Cyril H.
- Bertotti, Andrea
- Trusolino, Livio
- Wessels, Lodewyk
- Garnett, Mathew J.
- Venue
- Nature
- Published
- 2022-02-23
- Volume
- 603
- Issue
- 7899
- Pages
- 166-173
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC8891012
- OpenAlex
- W4212966936
- Cited by
- 469
- References
- 43
- Citations by year
- 2026: 87 · 2025: 131 · 2024: 124 · 2023: 88 · 2022: 38
- FWCI
- 51.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Research Repository (Delft University of Technology) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- Wellcome Trust (206194)
- Cancer Research UK
- Ministero della Salute
- Associazione Italiana per la Ricerca sul Cancro
- Horizon 2020 Framework Programme
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug synergy, breast cancer cell lines, colorectal cancer cell lines, pancreatic cancer cell lines, targeted therapy, combination biomarkers, irinotecan, KRAS mutation, TP53 mutation, microsatellite stable, basal-like breast cancer, apoptosis
- MeSH terms
- Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Drug Combinations, Drug Synergism, Humans, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.